Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Percentage of Participants With Objective Response — 92.3 percentage of participants

Primary: Percentage of Participants Who Were Alive and Free From Progressive Disease — 88.28; 76.03 percentage of participants

Primary: Objective Response Rate — .85 proportion of patients

Primary: Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR) — 51; 15 Participants

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…

Primary: Number of Participants With Overall Response Rate (ORR) — 0; 0; 0; 0 participants

Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants

Primary: Progression-Free Survival (PFS) as Assessed by Investigator — 42.02; 32.76 months — p=0.0231

Primary: Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction — 2 Participants

Primary: Overall Response Rate (ORR) — 59.7 percentage of participants — p=<=0.0001

Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities

Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33

Primary: Percentage of Participants With Administration-Associated Reactions (AARs) — 1.1; 3.7; 1.6; 1.1 Percentage of Participants %

Primary: Objective Response Rate (ORR) — 48.7; 27.3 Percentage of participants

Primary: Percentage of Participants With Administration-Associated Reactions (AAR) — 4.2; 8.1; 6.3; 0 Percentage of Participants

Primary: Overall Response Rate (ORR) as Determined by IRRC — 4.3 Percentage of participants

Primary: Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle…

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography…

Primary: Percentage of Participants With Modalities of the Therapeutic Decision Before First Study Induction Treatment Phase — 81.9; 8.4; 6.3; 3.4 percentage of participants

Primary: Percentage of Participants With Progression of Disease at Year 2 (POD24) — 8.9 percentage of participants

Primary: Number of Participants With Complete Response at 3 Years — 30 Participants

Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants

Primary: Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab) — 6; 9; 10; 7 participants

Primary: Part A, Phase I — 0; 1; 3; 0 Participants

Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants

Primary: Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS) — 24.5 percentage of participants

Primary: Overall Response Rate — 12 Participants — p=0.044

Primary: Number of Participants With Objective Response (OR) — 0; 1; 2; 0 participants